Chris Chen, WuXi Biologics CEO (Anthony Kwan/Bloomberg via Getty Images)
WuXi Biologics seeks spinout, HK listing of bioconjugates-focused joint venture
Another member of the WuXi AppTec family is set to be spun off and separately listed on the Hong Kong Stock Exchange, allowing the contract …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.